Hyloris Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -17.1%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 38.2% per year.
Key information
-17.1%
Earnings growth rate
-4.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 38.2% |
| Return on equity | -38.2% |
| Net Margin | -190.8% |
| Next Earnings Update | 20 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hyloris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -13 | 6 | 14 |
| 31 Mar 24 | 6 | -14 | 6 | 14 |
| 31 Dec 23 | 4 | -15 | 6 | 14 |
| 30 Sep 23 | 3 | -14 | 5 | 13 |
| 30 Jun 23 | 3 | -13 | 5 | 11 |
| 31 Mar 23 | 3 | -12 | 4 | 11 |
| 31 Dec 22 | 2 | -12 | 4 | 10 |
| 30 Sep 22 | 3 | -10 | 3 | 9 |
| 30 Jun 22 | 3 | -8 | 3 | 8 |
| 31 Mar 22 | 3 | -10 | 3 | 7 |
| 31 Dec 21 | 3 | -12 | 3 | 5 |
| 30 Sep 21 | 2 | -12 | 2 | 4 |
| 30 Jun 21 | 1 | -12 | 1 | 3 |
| 31 Mar 21 | 1 | -10 | 2 | 3 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -8 | 3 | 2 |
| 30 Jun 20 | 0 | -8 | 3 | 2 |
| 31 Mar 20 | 0 | -6 | 1 | 2 |
| 31 Dec 19 | 0 | -5 | 1 | 1 |
| 31 Dec 18 | 0 | -6 | 1 | 5 |
| 31 Dec 17 | 0 | -4 | 2 | 2 |
Quality Earnings: 0AB6 is currently unprofitable.
Growing Profit Margin: 0AB6 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0AB6 is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare 0AB6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0AB6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: 0AB6 has a negative Return on Equity (-38.21%), as it is currently unprofitable.